Daily Endocrinology Research Analysis
Analyzed 41 papers and selected 3 impactful papers.
Summary
Translational advances and large-scale epidemiology in endocrinology stand out today. A gut-restricted TAS2R agonist (ARD-101) showed appetite and weight effects in humans with strong preclinical synergy with DPP-4 inhibition, a nationwide study linked diabetic neuropathy to elevated fracture risk, and a meta-analysis established sarcopenia as a marker of higher cardiovascular events.
Research Themes
- Gut-brain signaling and novel anti-obesity pharmacology
- Diabetes complications and skeletal health
- Muscle aging (sarcopenia) and cardiovascular risk stratification
Selected Articles
1. ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.
Across preclinical and randomized, placebo-controlled human studies, the gut-restricted TAS2R agonist ARD-101 decreased hunger and modestly reduced weight in adults over 28 days, while in obese mice it limited weight gain and, when combined with sitagliptin, produced substantial weight loss with metabolic benefits. Following tirzepatide discontinuation, switching to ARD-101 plus sitagliptin limited weight regain comparably to continued tirzepatide.
Impact: Introduces a novel, orally delivered, gut-restricted mechanism for appetite modulation with early human signals and strong preclinical synergy with DPP-4 inhibition, potentially expanding obesity pharmacotherapy options.
Clinical Implications: Supports further clinical development of TAS2R agonists as adjuncts or maintenance options (e.g., post-incretin therapy) and suggests exploring combination strategies with DPP-4 inhibitors to enhance weight control.
Key Findings
- In adults with obesity, ARD-101 reduced body weight by 0.8 kg at Day 28 and 1.3 kg at end-of-study versus placebo, and decreased hunger and food cravings.
- In DIO mice, DA (ARD-101) plus sitagliptin reduced body weight by 18.8% with metabolic benefits; DA alone reduced HFD-induced weight gain and improved glycemic and lipid measures.
- After tirzepatide cessation in DIO mice, switching to DA plus sitagliptin limited weight regain comparably to continued tirzepatide.
- In healthy participants, ARD-101 altered gut hormone levels, consistent with a gut-brain signaling mechanism.
Methodological Strengths
- Randomized, placebo-controlled human studies complemented by robust preclinical models
- Head-to-head and switch paradigms versus/after tirzepatide in mice to probe maintenance effects
Limitations
- Short human treatment duration (28 days) with modest weight loss and limited sample size not reported in abstract
- DPP-4 inhibitor synergy demonstrated preclinically; human combination data are lacking
Future Directions: Conduct longer, adequately powered Phase 2/3 RCTs to confirm efficacy, test combination with DPP-4 inhibitors in humans, and evaluate maintenance after GLP-1/GIP agonist withdrawal and targeted indications such as Prader-Willi syndrome.
OBJECTIVES: Obesity management has limited oral pharmacotherapies. Bitter taste receptor (TAS2R) agonists may modulate hunger, satiety, and metabolism via gut-brain signaling. We evaluated denatonium acetate (DA), a gut-restricted TAS2R agonist, across preclinical and clinical settings, and explored its combination with sitagliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor). METHODS: In mice transitioned to high-fat diet (HFD) or established with diet-induced obesity (DIO), we tested oral DA (20-80 mg/kg twice daily or 75 mg/kg once daily), a sitagliptin-formulated HFD, the combination, and subcutaneous tirzepatide, including a post-tirzepatide discontinuation phase, to assess weight trajectories and metabo
2. Sarcopenia and risk of cardiovascular events and mortality: a meta-analysis of longitudinal observational studies.
Pooling 100 longitudinal studies (~2.3 million participants), sarcopenia was associated with increased risk of subsequent cardiovascular events (adjusted RR 1.63). Low muscle mass and low grip strength showed similar associations, while associations with cardiovascular mortality attenuated after adjustment.
Impact: Establishes sarcopenia and its traits as clinically meaningful markers of elevated cardiovascular risk in longitudinal data, supporting integration into risk stratification.
Clinical Implications: Routine assessment of muscle mass and strength (e.g., grip strength) could refine cardiovascular risk stratification in older adults and inform preventive interventions (nutrition, resistance training).
Key Findings
- Sarcopenia was associated with higher cardiovascular events risk (aRR 1.63, 95% CI 1.30–2.04).
- Low muscle mass and low grip strength were each associated with increased cardiovascular events (aRR 1.43 and 1.46, respectively).
- Association with cardiovascular mortality was significant only in unadjusted analyses (uRR 2.28), attenuating after adjustment (aRR 1.61, 95% CI 0.98–2.64).
Methodological Strengths
- Large-scale meta-analysis including ~2.3 million participants across 100 longitudinal studies
- Use of random-effects models and adjusted risk estimates where available
Limitations
- Heterogeneity in sarcopenia definitions, measurement methods, and covariate adjustments
- Residual confounding and publication bias cannot be fully excluded
Future Directions: Prospective interventional trials to test whether improving muscle mass/strength reduces cardiovascular events, and standardization of sarcopenia definitions for risk prediction.
BACKGROUND: The burden of cardiovascular events remains substantial under current care, highlighting the clinical importance of identifying high-risk populations. Sarcopenia, affecting 10%-27% of older adults worldwide, is modifiable but under-recognised in cardiovascular prevention due to unclear risk associations. We aimed to clarify the association between sarcopenia and cardiovascular events risk. METHODS: PubMed, Embase, and Web of Science were searched for longitudinal studies reporting associations between sarcopenia or its related traits with cardiovascul
3. Diabetic neuropathy and fracture risk - a nation-wide case/control study.
Using Danish national registries (265,405 fracture cases and 778,466 controls), diabetic neuropathy independently increased fracture risk (OR 1.47), highest for possible painful neuropathy (OR 1.62). Risk elevation appeared stronger in men and younger individuals; T1D increased fracture risk (OR 1.68) whereas T2D did not (OR 0.93).
Impact: Quantifies neuropathy as an independent skeletal risk in diabetes at national scale, refining risk stratification beyond glycemia and informing targeted fall-prevention and bone health strategies.
Clinical Implications: Incorporate neuropathy status (especially painful neuropathy) into fracture risk assessments for people with diabetes, intensify fall-prevention, consider earlier DXA and bone-protective therapy in high-risk subgroups.
Key Findings
- Diabetic neuropathy was independently associated with higher fracture risk (OR 1.47, 95% CI 1.40–1.55), with the highest risk in possible painful neuropathy (OR 1.62).
- Fracture risk increased in T1D (OR 1.68, 95% CI 1.61–1.76) but not in T2D (OR 0.93, 95% CI 0.91–0.94).
- Risk elevation appeared stronger in men and younger individuals; site-specific analyses showed larger estimates for lower leg fractures and smaller for vertebral, hip, and lower arm.
Methodological Strengths
- Nationwide, population-based case-control design with very large sample size
- Rigorous matching and multivariable conditional logistic regression with site-specific analyses
Limitations
- Neuropathy classification based on diagnostic codes and analgesic prescriptions may misclassify painful vs painless neuropathy
- Residual confounding (e.g., falls risk factors, bone quality metrics) cannot be fully excluded in observational design
Future Directions: Prospective studies integrating falls data, bone density/quality metrics, and neuropathy phenotyping; interventional trials to test whether neuropathy treatment or fall-prevention reduces fractures.
INTRODUCTION/AIM: Fracture risk is increased in type 1 (T1D) and type 2 diabetes (T2D). Diabetic neuropathy may contribute to this risk. We examined the association between diabetes and fracture risk, and whether diabetic neuropathy, including possible painless and possible painful neuropathy, was associated with increased risk of fracture. METHODS: In this population-based case-control study, adults (≥18 years) with and without diabetes were identified using Danish health registries. All incident fractures (excluding skull/facial) from 2019 to 2021 were includ